Niaspan Titration Starter Pack is owned by Abbvie.

Niaspan Titration Starter Pack contains Niacin.

Niaspan Titration Starter Pack has a total of 5 drug patents out of which 5 drug patents have expired.

Expired drug patents of Niaspan Titration Starter Pack are:

• US7011848
• US6129930
• US6406715
• US6746691
• US6080428

Niaspan Titration Starter Pack was authorised for market use on 28 July, 1997.

Niaspan Titration Starter Pack is available in tablet, extended release;oral dosage forms.

Niaspan Titration Starter Pack can be used as an intermediate release nicotinic acid formulation suitable for oral administration once-a-day as a single dose for treating hyperlipidemia without causing drug-induced hepatotoxicity or elevations in uric acid or glucose or both, intermediate rel nicotinic acid formulations having unique urinary metab profiles resulting from absorption profiles of nicotinic acid from the intermediate nicotinic acid formulations,suitable for tx hyperlipidemia following qd dosing, method of treating hyperlipidemia with nicotinic acid by dosing once per day in the evening or at night, method of treating hyperlipidemia with nicotinic acid without causing treatment-limiting elevations in uric acid or glucose levels or causing liver damage, by dosing once per day in the evening or at night, a method of using a nicotinic acid formulation to reduce elevated tc, ldl-c and tg levels, and raise hdl-c levels in patients with hyperlipidemia.

The generics of Niaspan Titration Starter Pack are possible to be released after 27 May, 2017.